Challenges of Gene Editing Therapies for Genodermatoses

Genodermatoses encompass a wide range of inherited skin diseases, many of which are monogenic. Genodermatoses range in severity and result in early-onset cancers or life-threatening damage to the skin, and there are few curative options. As such, there is a clinical need for single-intervention treatments with curative potential. Here, we discuss the nascent field of gene editing for the treatment of genodermatoses, exploring CRISPR-Cas9 and homology-directed repair, base editing, and prime editing tools for correcting pathogenic mutations. We specifically focus on the optimisation of editing efficiency, the minimisation off-targets edits, and the tools for delivery for potential future therapies. Honing each of these factors is essential for translating gene editing therapies into the clinical setting. Therefore, the aim of this review article is to raise important considerations for investigators aiming to develop gene editing approaches for genodermatoses.

Automated summary

Genodermatoses, a group of inherited skin diseases, pose significant challenges due to their severity and limited treatment options. This review explores the emerging field of gene editing for genodermatoses, specifically discussing tools such as CRISPR-Cas9, homology-directed repair, base editing, and prime editing for correcting pathogenic mutations. The optimization of editing efficiency, minimization of off-target edits, and delivery tools are crucial for clinical translation. The aim of this review is to provide important considerations for researchers developing gene editing approaches for genodermatoses.